This trial is testing a new treatment for pancreatic cancer in patients with an inherited BRCA1 or BRCA2 mutation. The treatment involves a combination of drugs given through an IV, with the goal of determining if it is safe.
11 Primary · 4 Secondary · Reporting Duration: Within 48 hours of vitamin C treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: Autologous Hematopoietic Stem Cells · No Placebo Group · Phase 1
Age 18 - 70 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Massachusetts General Hospital||100.0%|